Method Development for Laser-Diffraction Particle-Size Analysis - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Method Development for Laser-Diffraction Particle-Size Analysis
The author examines the process of method development, with reference to ISO 13320:2009 and relevant monographs from the United States and European pharmacopoeias.

Pharmaceutical Technology
pp. 100-106

Particle size is a critical quality attribute for a diverse array of pharmaceutical products, from topical ointments to powders for pulmonary delivery. During recent decades, the unique attributes of laser-diffraction analysis have positioned it as the particle-sizing technique of choice for the resulting spectrum of pharmaceutical applications. Fast, nondestructive and suitable for a broad size range (0.1 to 3000 μm), laser diffraction lends itself to full automation. As a result, for many routine users, particle-size measurement is now simply a matter of loading the sample and pressing a button. However, streamlining measurement to this degree demands the development of a robust secure method that will consistently deliver reliable and reproducible data. This process is given considerable emphasis in the International Organization for Standardization's (ISO) 13320:2009 standard for laser diffraction released at the end of 2009, reflecting that understanding of this technique among industry has grown significantly during the past decade (1). There is a wealth of information to support method development, the success of which depends on a rigorous and systematic examination of the factors known to influence results.

The principles of laser diffraction

Understanding the basic principles of laser diffraction is essential for successful method development. Laser diffraction is an ensemble particle-sizing technique, which means it provides a result for the whole sample, rather than building up distributions from data for individual particles, in the way that, for example, image analysis or microscopy does. Particles illuminated in a collimated laser-beam scatter light over a range of angles. Large particles generate a high scattering intensity at relatively narrow angles to the incident beam, while smaller particles produce a lower intensity signal but at much wider angles. Using an array of detectors, laser-diffraction analyzers record the pattern of scattered light produced by the sample.

With the application of an appropriate model of light behavior the particle-size distribution of the sample can be determined from the scattering data, via a deconvolution step. The Mie theory and the Fraunhofer approximation (of Mie theory) are used routinely. ISO 13320:2009 provides a detailed description of both models but confirms Mie as the method of choice, especially for measurements across a wide dynamic range. The two models return similar results for large particle sizes, but Mie offers improved accuracy for finer materials. Furthermore, the inaccuracies that arise from the use of Fraunhofer are unpredictable. Both models assume that the measured particles are spherical, so for nonspherical samples the size distribution returned is one that is based on spherical equivalence.

Method development involves addressing the wider set of practical issues that flow from this underlying explanation of the basic principles of operation. United States Pharmacopeia (USP) General Chapter <429> states that laser diffraction involves the measurement of "a representative sample, dispersed at an adequate concentration in a suitable liquid or gas" (2). This statement neatly highlights three crucial aspects of laser-diffraction analysis: sampling, dispersion, and measurement conditions.


Obtaining a representative sample from a larger bulk is a major challenge with any kind of laboratory-based particle characterization technique. Sampling issues generate the greatest errors in laser-diffraction analysis, especially when measuring large particles or when the specification is based on size parameters close to the extremes of the distribution, such as the Dv95 (the particle size below which 95% of the volume of particles exists). This is because laser diffraction, as a volume-based technique, is extremely sensitive to small changes in the amount of coarse particles within the selected sample. ISO 13320:2009 expressly discourages the use of specifications based on the Dv100 for this reason. The effect of sampling on reproducibility increases with particle size and the width of the distribution, as the volume of sample required to ensure representative sampling of the coarse particle fraction increases. For this reason, it may be necessary to measure a large sample (often greater than 1–2 g) to ensure reproducible results. For wet-dispersion measurements, this will require the use of a large dispersant volume, to ensure the concentration of material is within the required range for accurate measurements (i.e., to ensure multiple scattering is avoided). A detailed discussion of sampling is beyond the remit of this paper, but ISO 14488 provides an extremely useful summary of the requirements for sampling during particle characterization studies (3).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here